Patent · US Active

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

US9907834B2 · kind B2 · utility

1Cited by

8References

8Claims

0Family size

Assignee

BIOMARIN PHARMACEUTICAL INC. · US

Inventors

Sherry Bullens · Novato, US
Stuart Bunting · Novato, US
Tianwei Chou · Novato, US
Augustus O. Okhamafe · Concord, US
Christopher P. Price · Aachen, DE
Daniel J. Wendt · Novato, US
Clarence Yap · Novato, US

Key dates

Filing date	Aug 1, 2016
Grant date	Mar 6, 2018
Priority date	—
Expiry date	Aug 1, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P19/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.